Clinical

According to the study published in Cancer, adjuvant chemotherapy in patients with early stage colon cancer results in clinically relevant improvement in overall survival.

The Pew Charitable Trusts has proposed several ideas to address substance use disorders by focusing on developing and supporting policies such as the proposed rule to increase the patient limit for qualifying physicians to treat opioid use disorders.

Despite their known risk, only half the women over 85 years of age in a cohort being evaluated had their baseline bone density tested prior to initiating treatment.

Many patients, 65 years or younger, are still receiving aggressive cancer treatment in their final months of life despite Choosing Wisely recommendations encouraging symptom-directed palliative care.

Although cancer care costs are rising, it is proportional to the total utilization of healthcare resources and spending growth is happening more in areas that have seen innovation, explained Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology.

Making medical decisions is not as easy as following the evidence. When dealing with people, there are a number of anomalies that influence the decisions someone might make.

Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin gene were found responsible for lack of response to interferon gamma.

During a clinical session at the annual meeting of the American Society of Clinical Oncology, researchers were tasked with sharing their data on any breakthroughs or leads with biomarkers for the new immunotherapies.

At the annual meeting of the American Society of Clinical Oncology, results were presented from a phase 1/2 trial in which patients with relapsed or refractory CD19+ B-cell malignancies were treated with CD19 CAR-T cells.

A study has found that an 8-gene signature score, combined with nodal status and tumor size, obtained from the EndoPredict breast cancer test might be more accurate at predicting the recurrence of breast cancer, compared with the recurrence score of Oncotype DX.

The ROCKET trial was halted last week following news of 3 patient deaths due to cerebral edema.